Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1993 Apr;67(4):641–643. doi: 10.1038/bjc.1993.119

P glycoprotein (P-gp) and drug resistance--time for reappraisal?

S B Kaye
PMCID: PMC1968337  PMID: 8097103

Full text

PDF
641

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck W. T., Cirtain M. C., Danks M. K., Felsted R. L., Safa A. R., Wolverton J. S., Suttle D. P., Trent J. M. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res. 1987 Oct 15;47(20):5455–5460. [PubMed] [Google Scholar]
  2. Bissett D., Graham M. A., Setanoians A., Chadwick G. A., Wilson P., Koier I., Henrar R., Schwartsmann G., Cassidy J., Kaye S. B. Phase I and pharmacokinetic study of rhizoxin. Cancer Res. 1992 May 15;52(10):2894–2898. [PubMed] [Google Scholar]
  3. Bradley G., Sharma R., Rajalakshmi S., Ling V. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res. 1992 Oct 1;52(19):5154–5161. [PubMed] [Google Scholar]
  4. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  5. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  6. Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991 Jul 12;66(1):85–94. doi: 10.1016/0092-8674(91)90141-k. [DOI] [PubMed] [Google Scholar]
  7. Coley H. M., Twentyman P. R., Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 1989 Dec 15;38(24):4467–4475. doi: 10.1016/0006-2952(89)90658-8. [DOI] [PubMed] [Google Scholar]
  8. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277–1287. doi: 10.1177/38.9.1974900. [DOI] [PubMed] [Google Scholar]
  9. Holzmayer T. A., Hilsenbeck S., Von Hoff D. D., Roninson I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 7;84(19):1486–1491. doi: 10.1093/jnci/84.19.1486. [DOI] [PubMed] [Google Scholar]
  10. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976 Nov 11;455(1):152–162. doi: 10.1016/0005-2736(76)90160-7. [DOI] [PubMed] [Google Scholar]
  11. Kerr D. J., Graham J., Cummings J., Morrison J. G., Thompson G. G., Brodie M. J., Kaye S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol. 1986;18(3):239–242. doi: 10.1007/BF00273394. [DOI] [PubMed] [Google Scholar]
  12. Kessel D., Botterill V., Wodinsky I. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 1968 May;28(5):938–941. [PubMed] [Google Scholar]
  13. Lum B. L., Kaubisch S., Yahanda A. M., Adler K. M., Jew L., Ehsan M. N., Brophy N. A., Halsey J., Gosland M. P., Sikic B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol. 1992 Oct;10(10):1635–1642. doi: 10.1200/JCO.1992.10.10.1635. [DOI] [PubMed] [Google Scholar]
  14. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17–24. doi: 10.1200/JCO.1991.9.1.17. [DOI] [PubMed] [Google Scholar]
  15. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991 May 15;83(10):708–712. doi: 10.1093/jnci/83.10.708. [DOI] [PubMed] [Google Scholar]
  17. Rodenburg C. J., Nooter K., Herweijer H., Seynaeve C., Oosterom R., Stoter G., Verweij J. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol. 1991 Apr;2(4):305–306. doi: 10.1093/oxfordjournals.annonc.a057941. [DOI] [PubMed] [Google Scholar]
  18. Rothenberg M., Ling V. Multidrug resistance: molecular biology and clinical relevance. J Natl Cancer Inst. 1989 Jun 21;81(12):907–910. doi: 10.1093/jnci/81.12.907. [DOI] [PubMed] [Google Scholar]
  19. Sonneveld P., Durie B. G., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992 Aug 1;340(8814):255–259. doi: 10.1016/0140-6736(92)92353-h. [DOI] [PubMed] [Google Scholar]
  20. Sonneveld P., Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol. 1990 Jun;75(2):208–211. doi: 10.1111/j.1365-2141.1990.tb02650.x. [DOI] [PubMed] [Google Scholar]
  21. Tsuruo T., Oh-hara T., Iida H., Tsukagoshi S., Sato Z., Matsuda I., Iwasaki S., Okuda S., Shimizu F., Sasagawa K. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 1986 Jan;46(1):381–385. [PubMed] [Google Scholar]
  22. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987 May;84(9):3004–3008. doi: 10.1073/pnas.84.9.3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst. 1991 Jan 16;83(2):111–116. doi: 10.1093/jnci/83.2.111. [DOI] [PubMed] [Google Scholar]
  24. Weinstein R. S., Jakate S. M., Dominguez J. M., Lebovitz M. D., Koukoulis G. K., Kuszak J. R., Klusens L. F., Grogan T. M., Saclarides T. J., Roninson I. B. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991 May 15;51(10):2720–2726. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES